Core Laboratories (CLB) Asset Writedowns and Impairment (2023 - 2026)

Core Laboratories' Asset Writedowns and Impairment history runs 4 years deep, the most recent figure standing at $168000.0 for Q1 2026.

• On a quarterly basis, Asset Writedowns and Impairment fell 73.87% year-over-year to $168000.0 in Q1 2026; TTM through Mar 2026 was -$441000.0, a 168.58% decrease from a year earlier, with the FY2025 full-year figure at $34000.0, down 96.94% from the prior year.
• Asset Writedowns and Impairment climbed to $168000.0 in Q1 2026 per CLB's latest filing, from -$2.4 million in the prior quarter.
• Across five years, Asset Writedowns and Impairment topped out at $1.1 million in Q1 2024 and bottomed at -$2.4 million in Q4 2025.
• The 4-year median for Asset Writedowns and Impairment is $643000.0 (2025), against an average of $336777.8.
• Across the five-year window, Asset Writedowns and Impairment grew 9.36% in 2024 and sank 73.87% in 2026, its largest moves.
• Year by year, Asset Writedowns and Impairment stood at $576000.0 in 2023, then jumped by 92.71% to $1.1 million in 2024, then slumped by 315.77% to -$2.4 million in 2025, then jumped by 107.01% to $168000.0 in 2026.
• Per Business Quant, the three latest CLB Asset Writedowns and Impairment figures stand at $168000.0 (Q1 2026), -$2.4 million (Q4 2025), and $809000.0 (Q3 2025).